Voxzogo(vosoritide)
Voxzogo (vosoritide) is a protein pharmaceutical. Vosoritide was first approved as Voxzogo on 2021-08-26. It is used to treat achondroplasia and dwarfism in the USA. It has been approved in Europe to treat achondroplasia. It is known to target atrial natriuretic peptide receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Voxzogo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vosoritide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VOXZOGO | BioMarin Pharmaceutical | N-214938 RX | 2021-11-19 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| voxzogo 0.4mg voxzogo 0.56mg voxzogo 1.2mg | New Drug Application | 2024-11-08 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VOSORITIDE, VOXZOGO, BIOMARIN PHARM | |||
| 2030-10-20 | ODE-449 | ||
| 2028-11-19 | ODE-387 | ||
| 2026-11-19 | NCE | ||
| 2026-10-20 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Achondroplasia | D000130 | — | Q77.4 | 2 | 6 | 4 | — | — | 12 |
| Dwarfism | D004392 | — | E34.31 | — | 4 | 2 | — | — | 6 |
| Bone diseases | D001847 | — | M89.9 | — | 1 | 1 | — | — | 2 |
| Musculoskeletal diseases | D009140 | — | — | — | 1 | 1 | — | — | 2 |
| Lordosis | D008141 | — | M40.5 | — | 1 | 1 | — | — | 2 |
| Congenital limb deformities | D017880 | — | Q74.9 | — | 1 | 1 | — | — | 2 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | 1 | — | — | 1 |
| Osteochondrodysplasias | D010009 | Orphanet_800 | G71.13 | — | — | 1 | — | — | 1 |
| Developmental bone diseases | D001848 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Turner syndrome | D014424 | Orphanet_881 | Q96 | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Gonadal dysgenesis | D006059 | — | — | — | 1 | — | — | — | 1 |
| Mucopolysaccharidosis iv | D009085 | — | E76.210 | 1 | 1 | — | — | — | 1 |
| Noonan syndrome | D009634 | Orphanet_648 | Q87.19 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vosoritide |
| INN | vosoritide |
| Description | Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia.
|
| Classification | Protein |
| Drug class | peptides: atrial natriuretic type substances |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707276 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11928 |
| UNII ID | 7SE5582Q2P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NPR2
NPR2
Organism
Homo sapiens
Gene name
NPR2
Gene synonyms
ANPRB
NCBI Gene ID
Protein name
atrial natriuretic peptide receptor 2
Protein synonyms
ANP-B, ANPR-B, atrial natriuretic peptide B-type receptor, Atrial natriuretic peptide receptor type B, GC-B, guanylate cyclase 2B, Guanylate cyclase B, guanylyl cyclase B, natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B), NPR-B
Uniprot ID
Mouse ortholog
Npr2 (230103)
atrial natriuretic peptide receptor 2 (Q8CGA9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Voxzogo – BioMarin Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
908 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use